Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P. Schlaich, Thomas Guldager Lauridsen, M Bellet et al.|The Lancet|2022Cited by 223
Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in AdherencePankaj Gupta, Maciej Tomaszewski, Alison Beech et al.|Hypertension|2017Cited by 194
Heart and vessel hypertrophy in hypertension: possibilities of regression.Renata Cífková, J Widimský, P Niederle et al.|PubMed|1987Cited by 4